

CORRESPONDENCE



RTS,S/AS01E Vaccine against Malaria

TO THE EDITOR: The results of the trial reported by Bejon et al. (Dec. 11 issue),¹ in which the malaria vaccine RTS,S/AS01E was administered to children in Kilifi, Kenya, and Korogwe, Tanzania, are impressive. However, there are methodologic issues in the measurement of protective efficacy in sites where the transmission of malaria is falling. In such areas, transmission becomes overdispersed, and measuring protective efficacy against malaria over short periods may be inappropriate.² For example, the high protective efficacy of intermittent preventive treatment for malaria in infants that was observed in the first clinical trial in Tanzania was probably exaggerated by a fall in transmission during the trial.³ Administration of the RTS,S vaccine in adults was shown to give short-lived protection,⁴ and in the study by Bejon et al.,¹ the incidence of malaria was highest in the placebo group between 3 and 5 months after vaccination. This combination of decreasing transmission and protection over time could lead to an overestimate of efficacy.

Reassuringly, the high protective efficacy was seen in both sites; however, the study was small, the risk of malaria was highly variable, and transmission was falling. Similarly, the SPf66 vaccine showed high protective efficacy in low-transmission⁵ but not high-transmission settings. Testing RTS,S in high-transmission sites is a priority in order to refine estimates of SPf66.

Roly D. Gosling, M.D.

Daniel Chandramohan, M.D., Ph.D.

London School of Hygiene and Tropical Medicine
London WC1E 7HT, United Kingdom
roly.gosling@lshtm.ac.uk

1. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. *N Engl J Med* 2008;359:2521-32.

2. Mwangi TW, Fegan G, Williams TN, Kinyanjui SM, Snow RW, Marsh K. Evidence for over-dispersion in the distribution of clinical malaria episodes in children. *PLoS ONE* 2008;3(5):e2196.

3. Gosling RD, Ghani AC, Deen JL, von Seidlein L, Greenwood BM, Chandramohan D. Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants? *Malar J* 2008;7:54.

4. Bojang KA, Milligan PJ, Pinder M, et al. Efficacy of RTS,S/AS02 malaria vaccine against *Plasmodium falciparum* infection in semi-immune adult men in The Gambia: a randomised trial. *Lancet* 2001;358:1927-34.

5. Valero MV, Amador LR, Galindo C, et al. Vaccination with SPf66, a chemically synthesised vaccine, against *Plasmodium falciparum* malaria in Colombia. *Lancet* 1993;341:705-10.

THE AUTHORS REPLY: In response to the comments by Gosling and Chandramohan: overdispersion in malaria is not necessarily limited to areas of falling transmission,¹ and it also occurs in infectious diseases other than malaria.² Our reading of the survival plots is of sustained transmission throughout the period of monitoring, although transmission has indeed been falling in the study areas.^{3,4} We certainly agree that estimates of efficacy during long-term follow-up are essential, and such estimates have been made for RTS,S/AS02A, with encouraging results.⁵ The data on vaccine efficacy

THIS WEEK'S LETTERS

- 1253 RTS,S/AS01E Vaccine against Malaria
- 1254 Antimalarial Therapies in Children from Papua New Guinea
- 1255 Smoking Exposure, 17q21 Variants, and Early-Onset Asthma
- 1256 Irbesartan for Heart Failure with Preserved Ejection Fraction
- 1259 Medical Mystery: Constipation — The Answer
- 1260 Cytokine Induction after Laboratory-Acquired West Nile Virus Infection

for RTS,S are significantly more consistent and encouraging than the data available for SPf66 at any stage of its development. The comparison may not be informative. Nevertheless, we agree with Gosling and Chandramohan that point estimates of vaccine efficacy from phase 2b studies, such as the results we report, are surrounded by uncertainty. RTS,S/AS01E will be evaluated in a wide range of transmission sites and over longer periods of follow-up in a planned phase 3 multicenter efficacy trial.

Philip Bejon, Ph.D.

Kenya Medical Research Institute
Kilifi, Kenya
pbejon@kilifi.kemri-wellcome.org

Amanda Leach, M.R.C.P.C.H.

GlaxoSmithKline Biologicals
1330 Rixensart, Belgium

Lorenz von Seidlein, Ph.D.

International Vaccine Institute
Seoul 151-500, Korea

1. Smith DL, Dushoff J, Snow RW, Hay SI. The entomological inoculation rate and *Plasmodium falciparum* infection in African children. *Nature* 2005;438:492-5.
2. Woolhouse ME, Dye C, Etard JF, et al. Heterogeneities in the transmission of infectious agents: implications for the design of control programs. *Proc Natl Acad Sci U S A* 1997;94:338-42.
3. Okiro EA, Hay SI, Gikandi PW, et al. The decline in paediatric malaria admissions on the coast of Kenya. *Malar J* 2007;6:151.
4. O'Meara WP, Bejon P, Mwangi TW, et al. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. *Lancet* 2008;372:1555-62.
5. Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of *Plasmodium falciparum* disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. *Lancet* 2005;366:2012-8.

Antimalarial Therapies in Children from Papua New Guinea

TO THE EDITOR: In their article on antimalarial combination therapies, Karunajeewa et al. (Dec. 11 issue)¹ conclude that artemether–lumefantrine has more favorable efficacy than dihydroartemisinin–piperazine, even though fat was given with the treatment only in the artemether–lumefantrine group and there was no significant difference in the primary end point. Their per-protocol analysis with a high dropout rate from a small sample results in overestimation of the risk of treatment failure and wide 95% confidence intervals (6.4% to 20.0%). We reanalyzed data from 981 children younger than 5 years of age who were treated with dihydroartemisinin–piperazine in seven clinical trials in Indonesia, Thailand, Uganda, and Burkina Faso. Dihydroartemisinin–piperazine was administered with milk or a biscuit. Overall, the recrudescence rate at day 42 was 3.1% (95% confidence interval, 1.9 to 4.3), ranging from 0 to 7.1%. The risk of recurrent malaria was significantly reduced after treatment with dihydroartemisinin–piperazine as compared with artemether–lumefantrine (odds ratio, 0.51; $P < 0.001$).

Dihydroartemisinin–piperazine is a highly effective treatment for multidrug-resistant *falciparum* malaria in young children and provides clinically significant post-treatment prophylaxis.²⁻⁴ We recommend that both dihydroartemisinin–piperazine and artemether–lumefantrine be given

with fat (milk, biscuit, or other food) to increase bioavailability.⁵

Ric N. Price, M.D.

Menzies School of Health Research
Darwin, NT 0811, Australia
rnp@menzies.edu.au

Grant Dorsey, M.D., Ph.D.

University of California
San Francisco, CA 94110

Francois Nosten, M.D., Ph.D.

Shoklo Malaria Research Unit
Mae Sod 63110, Thailand

Drs. Price and Nosten report serving as consultants to Medicine for Malaria Venture (MMV). No other potential conflict of interest relevant to this letter was reported.

1. Karunajeewa HA, Mueller I, Senn M, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. *N Engl J Med* 2008;359:2545-57.
2. Ratcliff A, Siswanto H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant *falciparum* and vivax malaria in Papua, Indonesia: an open-label randomised comparison. *Lancet* 2007;369:757-65.
3. Yeka A, Dorsey G, Kanya MR, et al. Artemether-lumefantrine versus dihydroartemisinin-piperazine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. *PLoS ONE* 2008;3(6):e2390.
4. Ashley EA, McGready R, Hutagalung R, et al. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperazine for the treatment of uncomplicated, multidrug-resistant *falciparum* malaria. *Clin Infect Dis* 2005;41:425-32.
5. Sim IK, Davis TM, Ilett KF. Effects of a high-fat meal on the relative oral bioavailability of piperazine. *Antimicrob Agents Chemother* 2005;49:2407-11.